Immuno-genomic landscape of osteosarcoma

Limited clinical activity has been seen in osteosarcoma (OS) patients treated with immune checkpoint inhibitors (ICI). To gain insights into the immunogenic potential of these tumors, we conducted whole genome, RNA, and T-cell receptor sequencing, immunohistochemistry and reverse phase protein array...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chia-Chin, Beird, Hannah C., Andrew Livingston, J., Advani, Shailesh, Mitra, Akash, Cao, Shaolong, Reuben, Alexandre, Ingram, Davis, Wang, Wei-Lien, Ju, Zhenlin, Hong Leung, Cheuk, Lin, Heather, Zheng, Youyun, Roszik, Jason, Wang, Wenyi, Patel, Shreyaskumar, Benjamin, Robert S., Somaiah, Neeta, Conley, Anthony P., Mills, Gordon B., Hwu, Patrick, Gorlick, Richard, Lazar, Alexander, Daw, Najat C., Lewis, Valerae, Futreal, P. Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035358/
https://www.ncbi.nlm.nih.gov/pubmed/32081846
http://dx.doi.org/10.1038/s41467-020-14646-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035358/
https://www.ncbi.nlm.nih.gov/pubmed/32081846
http://dx.doi.org/10.1038/s41467-020-14646-w

Ejemplares similares